Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720264 | 0.83 | POLB (0.41) | GRNSORT1KDM4EGAALMNA | |
| SCHEMBL2445416 | 0.83 | LMNA (0.41) | GRNSORT1KDM4EGAALMNA | |
| SCHEMBL19182678 | 0.83 | GAA (0.56) | GAALMNAPOLBCYP1A2CYP2C19 | |
| SCHEMBL353314 | 0.83 | GAA (0.56) | GAALMNAPOLBCYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL8355477 | 0.81 | GAA (0.55) | GAALMNAPOLBCYP1A2CYP2C19 | |
| SCHEMBL2347739 | 0.80 | GAA (0.47) | GRNSORT1GAALMNAPOLB | |
| SCHEMBL2903444 | 0.80 | LMNA (0.46) | GAALMNAPOLBRAB9ANOTUM | |
| SCHEMBL1194663 | 0.80 | LMNA (0.46) | GRNSORT1KDM4EGAALMNA | |
| SCHEMBL1195430 | 0.79 | LMNA (0.45) | GAALMNAPOLBCYP1A2CYP2C9 | |
| SCHEMBL6642192 | 0.75 | GAA (0.38) | KDM4EGAACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | NANTBIO, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-07-19 | — | — | US | disclosed |
| EP-2440554-B1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2016-10-05 | — | — | EP | disclosed |
| US-8802663-B2 | Pyrazole oxadiazole derivatives as S1P1 agonists | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| EP-2440554-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | Merck Serono S.A. (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2010142628-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO S.A. (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | KRAS, NRAS, HRAS | GRN 2642/4885SORT1 3651/4885KDM4E 3378/4885 |
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | S1PR1, S1PR3, S1PR2 | GRN 3229/4885SORT1 2822/4885KDM4E 3402/4885 |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | KRAS, NRAS, HRAS | GRN 2642/4885SORT1 3651/4885KDM4E 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.